Published in Medical Letter on the CDC and FDA, February 15th, 2004
Under the CRADA, Morphotek will apply its proprietary MORPHODOMA antibody technology to the development of novel antibodies for use in the treatment of pancreatic, ovarian, and lung cancers. The NCI will provide its expertise in characterizing and evaluating the lead antibodies for specificity and therapeutic efficacy.
"This agreement with the NCI is another valuable step in our company's goal of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.